Related Experiment Video

Updated: Aug 10, 2026

Turbidimetry on Human Washed Platelets: The Effect of the Pannexin1-inhibitor Brilliant Blue FCF on Collagen-induced Aggregation
09:13

Turbidimetry on Human Washed Platelets: The Effect of the Pannexin1-inhibitor Brilliant Blue FCF on Collagen-induced Aggregation

Published on: April 6, 2017

Platelet-suppressant therapy in patients with coronary artery disease

P Steele, J Rainwater, R Vogel

    JAMA
    |July 21, 1978
    PubMed

    Insights

    Platelet survival is shortened in most men with coronary artery disease and graft occlusion. Platelet-suppressant drugs improved survival and graft patency in these patients.

    Area of Science:

    • Cardiovascular Medicine
    • Hematology
    • Medical Research

    Background:

    • Platelets play a role in atherosclerosis and its complications like myocardial infarction and graft occlusion.
    • Shortened platelet survival is observed in patients with coronary artery disease.

    Purpose of the Study:

    • To investigate the relationship between platelet survival and coronary artery disease complications.
    • To evaluate the effect of platelet-suppressant drugs on platelet survival and graft patency.

    Main Methods:

    • Chromium-51 labeling was used to measure platelet survival in men with coronary artery disease.
    • Platelet survival was compared between patients with and without saphenous vein graft occlusion.
    • The impact of sulfinpyrazone, clofibrate, and dipyridamole on platelet survival and graft patency was assessed.

    Main Results:

    • Platelet survival was significantly shortened in 68% of men with coronary artery disease.
    • Shortened platelet survival was strongly associated with saphenous vein graft occlusion.
    • Platelet-suppressant drugs increased platelet survival and were linked to improved graft patency.

    Conclusions:

    • Shortened platelet survival is a significant factor in coronary artery disease and graft occlusion.
    • Platelet-suppressant medications show potential in improving outcomes for patients with coronary artery disease and graft issues.

    More Related Videos

    Interventional Diagnostic Procedure: A Practical Guide for the Assessment of Coronary Vascular Function10:28

    Interventional Diagnostic Procedure: A Practical Guide for the Assessment of Coronary Vascular Function

    Published on: March 15, 2022

    Microfluidics in Assessing Platelet Function06:47

    Microfluidics in Assessing Platelet Function

    Published on: November 8, 2024

    Related Concept Videos

    Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

    Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

    Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
    Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
    Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

    Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

    Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
    These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
    Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers01:26

    Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

    Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
    TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
    Coronary Artery Disease V: Interprofessional Care01:27

    Coronary Artery Disease V: Interprofessional Care

    Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
    Acute Coronary Syndrome IV: Interprofessional Care01:28

    Acute Coronary Syndrome IV: Interprofessional Care

    IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...
    Peripheral Artery Disease III: Interprofessional Care01:27

    Peripheral Artery Disease III: Interprofessional Care

    Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...